IVERIC bio Overview
- Founded
-
2007
- Status
-
Public
- Employees
-
163
- Stock Symbol
-
ISEE
- Investments
-
1
- Share Price
-
$37.72
- (As of Tuesday Closing)
IVERIC bio General Information
Description
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.
Contact Information
- 1249 South River Road
- Suite 107
- Cranbury, NJ 08512
- United States
IVERIC bio Timeline
IVERIC bio Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $37.72 | $38.05 | $8.85 - $38.25 | $5.22B | 138M | 3.43M | -$1.53 |
IVERIC bio Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 2,599,244 | 2,599,244 | 1,676,638 | 387,920 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (187,337) | (187,337) | (114,728) | (88,599) |
| Net Income | (185,211) | (185,211) | (114,522) | (84,547) |
| Total Assets | 666,823 | 666,823 | 389,358 | 216,754 |
| Total Debt | 97,768 | 97,768 | 1,571 | 115 |
IVERIC bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IVERIC bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
IVERIC bio Comparisons
Industry
Financing
Details
000000
000000
IVERIC bio Competitors (81)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Clearside Biomedical | Formerly VC-backed | Alpharetta, GA | 00 | 00000 | 000000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | Switzerland | 00 | 00000 | 000000000 | 00000 |
| 0000000 | Corporation | Leuven, Belgium | 00 | 0000 | 000000000 | 0000 |
| 000000 | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 | 00.000 |
| 0000000 0000000000 | Formerly VC-backed | Lexington, MA | 000 | 00000 | 000000&0 | 00000 |
IVERIC bio Patents
IVERIC bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020378982-A1 | Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd | Pending | 27-Oct-2019 | 000000000 | |
| CA-3156220-A1 | Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd | Pending | 27-Oct-2019 | 000000000 | |
| EP-4048288-A1 | Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd | Pending | 27-Oct-2019 | 000000000 | |
| US-20220370629-A1 | Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd | Pending | 27-Oct-2019 | 000000000 | |
| AU-2018370135-A1 | A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv) | Pending | 16-Nov-2017 | A61K47/60 |
IVERIC bio Executive Team (29)
IVERIC bio Board Members (16)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adrienne Graves Ph.D | Self | Chairman & Board Member | 000 0000 |
| Axel Bolte | Self | Director | 000 0000 |
| Calvin Roberts MD | Self | Board Member | 000 0000 |
| Christine Miller | Self | Board Member | 000 0000 |
| Glenn Sblendorio | IVERIC bio | Chief Executive Officer & Board Member | 000 0000 |
IVERIC bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
IVERIC bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
IVERIC bio Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 0 | 31-Oct-2018 | 0000000000 | Biotechnology |
IVERIC bio ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
29.52 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,480
Rank
Percentile
Pharmaceuticals
Industry
00 of 905
Rank
Percentile
Biotechnology
Subindustry
00 of 404
Rank
Percentile
